1
|
Egerer A, Schaefer Z, Larson L. A point-of-care dot blot ELISA assay for detection of protective antibody against canine adenovirus, canine parvovirus, and canine distemper virus is diagnostically accurate. J Am Vet Med Assoc 2022; 260:1928-1933. [PMID: 36198054 DOI: 10.2460/javma.22.05.0224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine diagnostic accuracy of a point-of-care antibody-screening test by determining sensitivity, specificity, and overall accuracy when compared to reference standard tests for antibody against core vaccine viruses canine adenovirus (CAV), canine parvovirus (CPV), and canine distemper virus (CDV). A further aim was to provide the practitioner with information to guide selection of vaccinal antibody testing methods. SAMPLES Canine sera from across North America were submitted to a fee-for-service titer-testing laboratory. Samples came from healthy pet dogs with known core vaccination history (n = 431) as well as unvaccinated dogs held in isolation (132). This study examined a total of 563 samples for CDV/CPV and 183 for CAV. PROCEDURES Serum virus neutralization assays determined antibody titers for CDV and CAV. Hemagglutination inhibition assay determined antibody titers against CPV. All sera were also tested by point-of-care dot blot ELISA (index test). RESULTS For all 3 viral antigens, the index test provided sensitivity ranging from 96.03% to 96.75% and specificity ranging from 87.50% to 94.33%. Overall accuracy ranged from 93.43% to 95.91%. CLINICAL RELEVANCE The index test correlates well with reference standard tests and is a reliable, rapid screening test for detection of protective vaccinal antibody against CAV, CDV, and CPV in healthy dogs over 20 weeks of age. An accurate assessment of immunity allows clinicians to administer core vaccines appropriately as needed, avoiding unnecessary risk of adverse vaccine events.
Collapse
|
2
|
Bergmann M, Freisl M, Hartmann K. [Prevention of canine parvovirosis - Part 1: Humoral and cellular immunity]. TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE 2021; 49:44-50. [PMID: 33588464 DOI: 10.1055/a-1319-4564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Canine parvovirosis remains a common and highly infectious disease. Thus, adequate protection is essential for all dogs at any time. In this, humoral immunity plays an essential role. The presence of antibodies in adult dogs suggests immunity against the disease, and nearly all adult dogs possess antibodies (either due to previous vaccination or infection). Meanwhile, worldwide vaccination guidelines recommend measurement of pre-vaccination antibodies instead of regular triennial re-vaccinations in adult dogs. Studies have demonstrated a long lasting duration of immunity against canine parvovirus. Re-vaccination therefore possesses no beneficial effect when dogs already have pre-vaccination antibodies. Thus, when antibodies are present, unnecessary re-vaccinations that potentially cause vaccine-associated adverse events should be avoided. Hemagglutination inhibition and virus neutralization can be performed in specialized laboratories for quantitative antibody titer measurement. Semiquantitative point-of-care (POC) tests for detection of CPV antibodies are available. Since the presence of CPV antibodies in adult dogs that have been vaccinated or previously infected suggests adequate immunity against disease, these POC tests can be a useful tool in practice. They identify dogs that might potentially be unprotected and require re-vaccination during preventive health care appointments. Concerning the POC tests' quality assessment, a high specificity (low number of false positive test results) is considered the most important feature.
Collapse
Affiliation(s)
- Michèle Bergmann
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| | - Monika Freisl
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| | - Katrin Hartmann
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| |
Collapse
|
3
|
Decaro N, Buonavoglia C, Barrs VR. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication? Vet Microbiol 2020; 247:108760. [PMID: 32768213 PMCID: PMC7295477 DOI: 10.1016/j.vetmic.2020.108760] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 06/11/2020] [Accepted: 06/13/2020] [Indexed: 01/22/2023]
Abstract
Despite extensive vaccination, canine parvovirus (CPV) still represents one of the major causes of pups’ mortality. CPV immunisation failures occur frequently and recognize different reasons. Interference by maternally-derived antibodies is the main cause of CPV immunisation failures. Eradication of CPV infection is a challenge for the future, but it will not be achieved in a short time
Despite extensive vaccination, canine parvovirus (CPV) remains a leading infectious cause of canine mortality, especially among juveniles. This review provides an update on CPV vaccine types and vaccination protocols. The design of CPV prevention strategies and vaccination programs with a goal of herd immunity has been hampered by deficiencies of studies that model companion animal viral infections and inform an understanding of the basic reproduction number. However, the most important issue in eradication of CPV disease is represented by immunisation failures including: i) the presence of interfering titres of maternally-derived antibodies; ii) the presence of non-responders; and iii) possible reversion to virulence. In contrast, the role of the CPV variants in immunisation failures is widely debated. Taking into account the reduced circulation of canine distemper virus and canine adenovirus type 1 in countries where extensive vaccination is carried out, more effort should be made to aim for CPV eradication, including antibody testing to determine the optimal time for vaccinations of pups and adults and homogeneous vaccine coverage of dog population.
Collapse
Affiliation(s)
- N Decaro
- Department of Veterinary Medicine, University of Bari, Valenzano (Bari), Italy.
| | - C Buonavoglia
- Department of Veterinary Medicine, University of Bari, Valenzano (Bari), Italy
| | - V R Barrs
- City University of Hong Kong, Department of Infectious Diseases & Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, Kowloon, Hong Kong SAR, China
| |
Collapse
|
4
|
Vasu J, Srinivas MV, Antony PX, Thanislass J, Padmanaban V, Mukhopadhyay HK. Comparative immune responses of pups following modified live virus vaccinations against canine parvovirus. Vet World 2019; 12:1422-1427. [PMID: 31749576 PMCID: PMC6813607 DOI: 10.14202/vetworld.2019.1422-1427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Background and Aim: Canine parvovirus (CPV) is the most important viral cause of enteritis and mortality in pups. Evaluation and monitoring of pre- and post-vaccine immune responses may help to determine the efficacy of the current vaccination schedule being followed in pups in India. This study aimed to evaluate and monitor the pre- and post-vaccine immune responses of CPV vaccinated pups using hemagglutination inhibition (HI) assay. The neutralizing antibody titer levels were also detected using serum neutralization test (SNT). Materials and Methods: The pups were categorized into two groups, the double booster and the single booster groups. In this study, serum samples were subjected to HI and SNT for measuring the CPV antibody titer at frequent intervals for up to 6 months from 27 healthy pups following primary and booster CPV vaccinations. Results: The antibody titers in double booster pups reached their peaks at the 21st day after the second booster vaccination with a geometric mean (GM) of 3.57. The antibody titers in single booster pups reached their peaks at the 21st day after the first booster vaccination with a lower GM of 3.18. Conclusion: The double booster pups maintained a higher immune response throughout the period of the study compared to single booster pups though the difference in titers was not statistically significant. SNT results indicated that the raised antibody titer was also able to yield virus-neutralizing antibodies. No interfering maternally derived antibodies were found in the pups at the age of primary vaccination (45th day) in our study. Therefore, the second booster vaccination may be useful in maintaining the protective titer for a prolonged period.
Collapse
Affiliation(s)
- Jayalakshmi Vasu
- Department of Veterinary Microbiology, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| | - Mouttou Vivek Srinivas
- Department of Veterinary Microbiology, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| | - Prabhakar Xavier Antony
- Department of Veterinary Microbiology, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| | - Jacob Thanislass
- Department of Veterinary Biochemistry, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| | - Vijayalakshmi Padmanaban
- Department of Veterinary Medicine, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| | - Hirak Kumar Mukhopadhyay
- Department of Veterinary Microbiology, Rajiv Gandhi Institute of Veterinary Education and Research, Puducherry, India
| |
Collapse
|
5
|
Altman K, Kelman M, Ward M. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol 2017; 210:8-16. [DOI: 10.1016/j.vetmic.2017.08.019] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 08/26/2017] [Accepted: 08/28/2017] [Indexed: 11/16/2022]
|
6
|
Thomas J, Singh M, Goswami TK, Glora P, Chakravarti S, Chander V, Upmanyu V, Verma S, Sharma C, Mahendran K. Determination of immune status in dogs against CPV-2 by recombinant protein based latex agglutination test. Biologicals 2017; 49:51-56. [PMID: 28689674 DOI: 10.1016/j.biologicals.2017.06.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Revised: 06/24/2017] [Accepted: 06/27/2017] [Indexed: 11/19/2022] Open
Abstract
Canine parvoviral enteritis is a highly contagious viral illness caused by canine parvovirus-2 (CPV-2) which affects puppies of mainly 6-20 weeks of age. Vaccination is pivotal in preventing and controlling CPV-2 infection. Determination of antibody status is a critical determinant for successful vaccination. The hemagglutination inhibition (HI) test is 'gold standard' test for quantification of antibodies specific to CPV-2, although the execution of this test is not feasible under field conditions. The present study was undertaken to develop a point of care testing to determine immune status prior to CPV-2 vaccination or to detect seroconversion in immunized dogs by latex agglutination test (LAT) using recombinant antigen. Truncated portion of VP2 protein (tVP2) of CPV-2 was selected on the basis of antigenic indices, overexpressed the recombinant protein in E. coli system and was subsequently used in development of LAT. A total of 59 serum samples obtained from vaccinated (n = 54) and healthy unvaccinated (n = 5) dogs were tested. The positivity was observed in 85% (46/54) of these dogs with varying agglutination pattern. The overall sensitivity and specificity of latex agglutination test in comparison to HI test was recorded as 90% and 88% respectively with an agreement value of 90% (CI = 95%).
Collapse
Affiliation(s)
- Jobin Thomas
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Mithilesh Singh
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India.
| | - T K Goswami
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Philma Glora
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Soumendu Chakravarti
- Biological Product Division, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Vishal Chander
- CADRAD, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Vikramaditya Upmanyu
- Biological Standardization Division, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Suman Verma
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - Chhavi Sharma
- Immunology Section, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| | - K Mahendran
- Division of Medicine, Indian Veterinary Research Institute, Izatnagar Bareilly, 243122, India
| |
Collapse
|
7
|
Maurin-Bernaud L, Goutebroze S, Merdy O, Chanay A, Cozette V, Le Gros FX. Efficacy of a new attenuated duck parvovirosis vaccine in Muscovy ducks. Vet Rec 2014; 175:281. [PMID: 25053270 DOI: 10.1136/vr.102584] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The efficacy of a new live attenuated parvovirosis vaccine was tested in conventional ducklings against Derzsy's disease by comparing two vaccination regimens. Ducklings were vaccinated with either one injection at 17 days of age or two injections at 1 and 17 days of age. Controls and vaccinated ducklings were challenged with a virulent Derzsy strain at 21 days of age (day 20). Weight was measured on days 20, 34 and 42/43. Surviving birds were necropsied on day 42/43. Protection rates were significantly higher in the groups vaccinated once (90 per cent, P=0.003) and twice (95 per cent, P<0.001) than in the control group (59 per cent). The bodyweight was significantly higher in both vaccinated groups than in the control group on day 34 (P=0.008 and P<0.001, respectively) and day 42/43 (P<0.001 for both groups). The growth was significantly higher in the group vaccinated twice than the group vaccinated once on day 34 (P=0.047) and day 42/43 (P=0.017). Both vaccination regimens provided a quick onset of immunity. The higher weight gain in the group vaccinated twice suggests that an early vaccination at hatchery followed by a second injection at 17 days of age is an optimal and practical schedule to prevent parvovirosis.
Collapse
Affiliation(s)
- L Maurin-Bernaud
- Merial S.A.S. - Centre de Recherche de Saint Vulbas, Parc Industriel de la Plaine de l'Ain, Allée des Cyprès, Saint Vulbas 01150, France
| | - S Goutebroze
- Merial S.A.S. - Centre de Recherche de Saint Vulbas, Parc Industriel de la Plaine de l'Ain, Allée des Cyprès, Saint Vulbas 01150, France
| | - O Merdy
- Merial S.A.S. - Centre de Recherche de Saint Vulbas, Parc Industriel de la Plaine de l'Ain, Allée des Cyprès, Saint Vulbas 01150, France
| | - A Chanay
- Merial S.A.S. - Centre de Recherche de Saint Vulbas, Parc Industriel de la Plaine de l'Ain, Allée des Cyprès, Saint Vulbas 01150, France
| | - V Cozette
- Merial S.A.S. - 254 rue Marcel Mérieux, Lyon 69007, France
| | - F-X Le Gros
- Merial S.A.S. - 254 rue Marcel Mérieux, Lyon 69007, France
| |
Collapse
|
8
|
Elia G, Desario C, Pezzoni G, Camero M, Brocchi E, Decaro N, Martella V, Buonavoglia C. Recombinant ELISA using baculovirus-expressed VP2 for detection of antibodies against canine parvovirus. J Virol Methods 2012; 184:98-102. [DOI: 10.1016/j.jviromet.2012.05.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2012] [Revised: 05/22/2012] [Accepted: 05/24/2012] [Indexed: 10/28/2022]
|
9
|
Abstract
Since its emergence in 1978, canine parvoviral enteritis has remained a common and important cause of morbidity and mortality in young dogs. The continued incidence of parvoviral enteritis is partly due to the virus's capability to "reinvent" itself and evolve into new, more virulent and resistant subspecies. This article reviews current knowledge about the virus, its epidemiology, clinical manifestation, diagnosis, management, and prevention.
Collapse
Affiliation(s)
- Amelia Goddard
- Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria 0110, South Africa.
| | | |
Collapse
|
10
|
Ntafis V, Xylouri E, Kalli I, Desario C, Mari V, Decaro N, Buonavoglia C. Characterization of Canine parvovirus 2 variants circulating in Greece. J Vet Diagn Invest 2010; 22:737-40. [PMID: 20807931 DOI: 10.1177/104063871002200512] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aim of the present study was to characterize Canine parvovirus 2 (CPV-2) variants currently circulating in Greece. Between March 2008 and March 2009, 167 fecal samples were collected from diarrheic dogs from different regions of Greece. Canine parvovirus 2 was detected by standard polymerase chain reaction, whereas minor groove binder probe assays were used to distinguish genetic variants and discriminate between vaccine and field strains. Of 84 CPV-2-positive samples, 81 CPV-2a, 1 CPV-2b, and 2 CPV-2c were detected. Vaccine strains were not detected in any sample. Sequence analysis of the VP2 gene of the 2 CPV-2c viruses revealed up to 100% amino acid identity with the CPV-2c strains previously detected in Europe. The results indicated that, unlike other European countries, CPV-2a remains the most common variant in Greece, and that the CPV-2c variant found in Europe is also present in Greece.
Collapse
Affiliation(s)
- Vasileios Ntafis
- Agricultural University of Athens, Faculty of Animal Science and Aquaculture, Athens, Greece
| | | | | | | | | | | | | |
Collapse
|
11
|
De Cramer KGM, Stylianides E, van Vuuren M. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. Vet Microbiol 2010; 149:126-32. [PMID: 21111542 DOI: 10.1016/j.vetmic.2010.11.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2010] [Revised: 10/19/2010] [Accepted: 11/01/2010] [Indexed: 10/18/2022]
Abstract
Seroconversion after early vaccination at four weeks against canine parvovirus (CPV) using a high antigen titre vaccine was evaluated in 121 puppies from three breeds of dogs housed in kennels representative of the private practitioner's environment. The trial included 52 German shepherd pups, 25 Rottweiler pups and 44 Boerboel pups. From each group 11, 4, and 18 puppies acted as control dogs, respectively. Depending on the different groups, puppies were vaccinated at 4, 6, 9 and 12 weeks. The experimental group differed from the control group in that they received the high titre vaccine at 4 weeks of age, whereas the control group was not vaccinated at 4 weeks. Blood was collected from all pups prior to vaccination to measure maternally derived colostral antibody. The results indicated that vaccination at 4 weeks of age in pups with high maternally derived antibody levels, results in seroconversion rates that may lead to a reduction in the window of susceptibility with respect to CPV infection. The implications of the findings with respect to dogs in heavily contaminated environments are discussed.
Collapse
|
12
|
Ntafis V, Mari V, Danika S, Fragkiadaki E, Buonavoglia C. An outbreak of canine coronavirus in puppies in a Greek kennel. J Vet Diagn Invest 2010; 22:320-3. [PMID: 20224103 DOI: 10.1177/104063871002200231] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Canine coronavirus (CCoV) is usually the cause of mild gastroenteritis in dogs and is known to have spread worldwide. However, to date, no CCoV cases have been confirmed in Greece. In the present work, the authors investigated an outbreak of enteritis in puppies from a Greek kennel for the presence of CCoV. Dogs were presented with clinical signs of diarrhea, anorexia, weakness, depression, dehydration, and 1 death. Canine coronavirus type II was detected by reverse transcription nested polymerase chain reaction in all 11 puppies, whereas 1 puppy presented dual infection with CCoV type II and canine parvovirus 2. Surprisingly, sequence analysis of the samples revealed higher similarity to the pantropic CCoV II strain CB/05 than to other reference strains, in the most variable region of the S gene.
Collapse
Affiliation(s)
- Vasileios Ntafis
- Agricultural University of Athens, Iera Odos 75, 118 55, Athens, Greece.
| | | | | | | | | |
Collapse
|
13
|
Martella V, Cavalli A, Decaro N, Elia G, Desario C, Campolo M, Bozzo G, Tarsitano E, Buonavoglia C. Immunogenicity of an intranasally administered modified live canine parvovirus type 2b vaccine in pups with maternally derived antibodies. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2005; 12:1243-5. [PMID: 16210491 PMCID: PMC1247831 DOI: 10.1128/cdli.12.10.1243-1245.2005] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The ability of a modified live canine parvovirus type 2b vaccine to elicit active immunization in pups with maternally derived antibodies (MDA) by intranasal administration was evaluated. The vaccine induced seroconversion in 100% of pups with MDA titers of < or = 80 and in 51.6% of pups with titers between 160 and 320.
Collapse
Affiliation(s)
- Vito Martella
- Department of Animal Health and Well-Being, Faculty of Veterinary Medicine, University of Bari, S.p. per Casamassima km 3, 70010 Valenzano, Bari, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Decaro N, Campolo M, Desario C, Elia G, Martella V, Lorusso E, Buonavoglia C. Maternally-derived antibodies in pups and protection from canine parvovirus infection. Biologicals 2005; 33:261-7. [PMID: 16168665 DOI: 10.1016/j.biologicals.2005.06.004] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2005] [Revised: 06/14/2005] [Accepted: 06/16/2005] [Indexed: 11/16/2022] Open
Abstract
The interaction between maternally-derived antibodies (MDA) and canine parvovirus (CPV) infection was evaluated in five groups of pups with a wide range of haemagglutination inhibiting (HI) titres of MDA (from < 10 to 320). The pups were inoculated with a field CPV strain and monitored daily to evaluate their clinical condition and viral shedding in the faeces. Serum samples were collected weekly to evaluate antibody response. Clinical signs were observed in dogs with HI titres up to 80. Active CPV replication was demonstrated in dogs with HI titres up to 160, although slightly delayed, at lower titres and for a shorter period compared to seronegative dogs. The successful infection of dogs with HI titres of 80 and 160 was also confirmed by seroconversion, evaluated at day 14 postinfection. These findings are in contrast with the MDA titre (HI > or = 80) usually considered fully protective for CPV infection, and suggest the need for revision of current vaccination programmes for pups.
Collapse
Affiliation(s)
- Nicola Decaro
- Department of Animal Health and Well-being, Faculty of Veterinary Medicine of Bari, Strada per Casamassima km 3, 70010 Valenzano, Bari, Italy.
| | | | | | | | | | | | | |
Collapse
|
15
|
Immunogenicity of an intranasally administered modified live canine parvovirus type 2b vaccine in pups with maternally derived antibodies. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2005. [PMID: 16210491 DOI: 10.1128/cdli.12.10.1243–1245.2005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The ability of a modified live canine parvovirus type 2b vaccine to elicit active immunization in pups with maternally derived antibodies (MDA) by intranasal administration was evaluated. The vaccine induced seroconversion in 100% of pups with MDA titers of < or = 80 and in 51.6% of pups with titers between 160 and 320.
Collapse
|
16
|
Pratelli A, Cavalli A, Normanno G, De Palma MG, Pastorelli G, Martella V, Buonavoglia C. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b). JOURNAL OF VETERINARY MEDICINE. B, INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH 2000; 47:273-6. [PMID: 10861195 DOI: 10.1046/j.1439-0450.2000.00340.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The results of vaccination trials carried out on pups with maternally derived antibodies (MDA) to canine parvovirus (CPV), using a modified-live CPV-2b variant vaccine (29-97/40 strain), are reported. The vaccine was able to overcome the obstacle of MDA, and to elicit protective immunity in 100% of the pups whose antibody titres were 1:10-1:40, 83% of the pups with titres of 1:80, 57% of the pups with titres of 1:160, and even in 60% of the pups with antibody titres of 1:320.
Collapse
Affiliation(s)
- A Pratelli
- Department of Health and Animal Welfare, Faculty of Veterinary Medicine, Bari, Italy
| | | | | | | | | | | | | |
Collapse
|
17
|
Olson P, Hedhammar Å, Klingeborn B. Canine parvovirus infection, canine distemper and infectious canine hepatitis: inclination to vaccinate and antibody response in the Swedish dog population. Acta Vet Scand 1997. [PMID: 9050276 DOI: 10.1186/bf03548083] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The inclination of dog owners to vaccinate was investigated by sending a questionnaire to randomly selected Swedish dog-owning households. According to the owners (n = 538), 86.7% of the dogs had been vaccinated against CPV and 95.8% had been vaccinated against CD/ICH. The inclination to vaccinate mixed breeds was significantly lower than the inclination to vaccinate pure-bred dogs. In a second study titres of CPV, CD and CAV-1 virus antibodies were measured in 176 randomly selected dogs with known vaccination histories. CPV antibody titres > or = 1:80 were detected in 70.9% of the CPV vaccinated dogs. There was a significant difference in the fraction of dogs with CPV titre > or = 1:80 between the group last vaccinated with live attenuated vaccine and the group last vaccinated with inactivated vaccine. Titres of CD and CAV-1 virus antibodies > or = 1:16 were found in 86.1% and 91.6% of the vaccinated dogs respectively. The fraction of dogs with CAV-1 antibody titres > or = 1:16 was significantly greater in the group that received inactivated CAV-1 vaccine than in the group vaccinated with attenuated live CAV-2 vaccine. Approximately 50% of the dogs were booster vaccinated against all 3 diseases at one year of age.
Collapse
|
18
|
Waner T, Naveh A, Wudovsky I, Carmichael LE. Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay. J Vet Diagn Invest 1996; 8:427-32. [PMID: 8953526 DOI: 10.1177/104063879600800404] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Interference caused by maternal antibodies is considered a major cause of canine parvovirus (CPV) vaccination failure. In this study, an immunoblot clinic-based enzyme-linked immunosorbent assay (ELISA) method was used to detect CPV antibodies in sera of pregnant bitches and their offspring to study the response of pups to vaccination. With a easily accessible procedure for CPV antibody determination, the veterinarian should be able to gauge the response of pups after vaccination. The validity of the technique was tested in parallel against the standard hemagglutination inhibition (HI) test. Results of the ELISA were correlated with those of the standard HI method for quantification of CPV antibodies. With the ELISA, successfully immunized pups were identified, allowing for a more reliable and cost-effective program of vaccination. This simple clinic-based test could be used for the assessment of vaccination status of pups during the critical phase of 6 to about 16 weeks of age. This study is the first in which vaccination response to CPV in pups was followed, using a clinic-based ELISA for CPV antibody monitoring.
Collapse
Affiliation(s)
- T Waner
- Life Science Research Israel, Ness Ziona, Israel
| | | | | | | |
Collapse
|
19
|
Buonavoglia C, Cavalli A, Gravino E, Voigt V, Buonavoglia D, de Caprariis D. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus. ZENTRALBLATT FUR VETERINARMEDIZIN. REIHE B. JOURNAL OF VETERINARY MEDICINE. SERIES B 1994; 41:3-8. [PMID: 7941844 DOI: 10.1111/j.1439-0450.1994.tb00199.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The modified live canine parvovirus (CPV) vaccine was used to vaccinate intranasally twenty-five pups with maternal antibody. The vaccine was able to overcome the interference of maternal immunity in rates of 100%, 72.7% and 17.6% in pups with haemagglutination inhibition antibody titre of 40, 80 and 160 respectively.
Collapse
Affiliation(s)
- C Buonavoglia
- Istituto di Malattie Infettive e Parassitarie degli Animali, Facoltà di Medicina Veterinaria, Università Bari, Italia
| | | | | | | | | | | |
Collapse
|